NCT07403266 2026-02-11
Spectrum
Oils4Cure
Phase 3 Recruiting
Clinical Trials
10 trialsNCT02962414 2026-02-03
Roll-over Study to Collect and Assess Long-term Safety of Everolimus in Patients With TSC and Refractory Seizures Who Have Completed the EXIST-3 Study [CRAD001M2304] and Who Are Benefitting From Continued Treatment
Novartis
Phase 3 Active not recruiting
NCT05604170 2025-10-01
Open-label Study of Adjunctive GNX Treatment in Children and Adults With TSC-related Epilepsy
Marinus Pharmaceuticals
Phase 3 Terminated
NCT05323734 2025-07-11
Adjunctive GNX Treatment Compared With Placebo in Children and Adults With TSC-related Epilepsy
Marinus Pharmaceuticals
Phase 3 Completed
NCT05495425 2024-11-22
Clinical Study of NPC-12Y Gel in Patients With Skin Lesions Associated With TSC
Nobelpharma
Phase 3 Completed
NCT01906866 2024-04-23
Efficacy and Safety of CircadinĀ® in the Treatment of Sleep Disturbances in Children With Neurodevelopment Disabilities
Neurim Pharmaceuticals Ltd.
Phase 3 Completed
NCT02544750 2022-07-14
An Open-label Extension Trial of Cannabidiol (GWP42003-P, CBD) for Seizures in Tuberous Sclerosis Complex (GWPCARE6)
Jazz Pharmaceuticals
Phase 3 Completed
NCT02634931 2019-02-20
Long-term Trial of Topical Sirolimus to Angiofibroma in Patient With Tuberous Sclerosis Complex
Nobelpharma
Phase 3 Completed
NCT02635789 2017-02-02
Phase III Trial of Topical Formulation of Sirolimus to Skin Lesions in Patients With Tuberous Sclerosis Complex (TSC)
Nobelpharma
Phase 3 Completed
NCT00789828 2016-02-03
EXIST-1
Novartis
Phase 3 Completed